Sanne N van Munster, Eva P D Verheij, Özge Ozdemir, Esther Toes-Zoutendijk, Iris Lansdorp-Vogelaar, Esther A Nieuwenhuis, Cary C Cotton, Bas L A M Weusten, Lorenza Alvarez Herrero, Alaa Alkhalaf, B Ed Schenk, Erik J Schoon, Wouter L Curvers, Arjun D Koch, Pieter-Jan F de Jonge, Thjon J Tang, Wouter B Nagengast, Jessie Westerhof, Martin H M G Houben, Nicholas J Shaheen, Jacques J G H M Bergman, Roos E Pouw
BACKGROUND AND AIMS: Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett's neoplasia do not consider the risk of mortality from other causes than esophageal adenocarcinoma (EAC). We aimed to evaluate this risk during long-term FU, and to assess whether the Charlson Comorbidity Index (CCI) can predict mortality. METHODS: We included all patients with successful EET from the nationwide Barrett-registry in the Netherlands. Data were merged with National Statistics for accurate mortality data...
March 4, 2024: Gastroenterology